Principal Financial Group Inc. Buys 4,166 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Principal Financial Group Inc. increased its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 479,255 shares of the company’s stock after purchasing an additional 4,166 shares during the quarter. Principal Financial Group Inc. owned 0.28% of Option Care Health worth $11,119,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of OPCH. UMB Bank n.a. lifted its holdings in shares of Option Care Health by 41.7% during the 4th quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock worth $27,000 after acquiring an additional 346 shares during the period. International Assets Investment Management LLC raised its position in Option Care Health by 3,029.7% during the third quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock valued at $91,000 after purchasing an additional 2,757 shares in the last quarter. Quarry LP lifted its stake in Option Care Health by 327.7% during the third quarter. Quarry LP now owns 3,430 shares of the company’s stock worth $107,000 after purchasing an additional 2,628 shares during the last quarter. Blue Trust Inc. lifted its stake in Option Care Health by 16.9% during the fourth quarter. Blue Trust Inc. now owns 4,703 shares of the company’s stock worth $109,000 after purchasing an additional 681 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Option Care Health by 16.2% in the 3rd quarter. KBC Group NV now owns 5,013 shares of the company’s stock valued at $157,000 after purchasing an additional 700 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Option Care Health Stock Up 0.2 %

Shares of NASDAQ OPCH opened at $33.20 on Friday. The company has a 50 day simple moving average of $28.49 and a 200 day simple moving average of $28.07. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. Option Care Health, Inc. has a 1 year low of $21.39 and a 1 year high of $34.17. The firm has a market cap of $5.65 billion, a PE ratio of 27.90, a price-to-earnings-growth ratio of 2.30 and a beta of 1.35.

Analyst Upgrades and Downgrades

OPCH has been the subject of a number of research analyst reports. The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $38.00 to $27.00 in a report on Monday, November 4th. JMP Securities reissued a “market outperform” rating and set a $30.00 target price (down previously from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and raised their price target for the company from $26.00 to $35.00 in a research note on Thursday, January 23rd. UBS Group began coverage on shares of Option Care Health in a report on Thursday, December 5th. They set a “neutral” rating and a $26.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Option Care Health has a consensus rating of “Moderate Buy” and an average target price of $32.88.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.